SEC FORM
3
SEC Form 3
FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
OMB APPROVAL |
OMB Number: |
3235-0104 |
Estimated average burden |
hours per response: |
0.5 |
|
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 07/30/2014
|
3. Issuer Name and Ticker or Trading Symbol
HEALTHEQUITY INC
[ HQY ]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
Director |
X |
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
5. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Form filed by One Reporting Person |
X |
Form filed by More than One Reporting Person |
|
Table I - Non-Derivative Securities Beneficially Owned |
1. Title of Security (Instr.
4)
|
2.
Amount of Securities Beneficially Owned (Instr.
4)
|
3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivative Security (Instr.
4)
|
2. Date Exercisable and Expiration Date
(Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr.
4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
6. Nature of Indirect Beneficial Ownership (Instr.
5)
|
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Series C Preferred Stock |
|
|
Common Stock |
7,157,346 |
|
D |
|
Series D-1 Preferred Stock |
|
|
Common Stock |
5,152,986 |
|
D |
|
Series D-2 Preferred Stock |
|
|
Common Stock |
909,090 |
|
D |
|
Series D-3 Preferred Stock |
|
|
Common Stock |
825,868 |
|
D |
|
Stock Option (right to buy) |
|
03/26/2019 |
Common Stock |
30,000 |
1.1 |
D |
|
Stock Option (right to buy) |
|
01/17/2017 |
Common Stock |
30,000 |
1.1 |
D |
|
Stock Option (right to buy) |
|
01/17/2018 |
Common Stock |
30,000 |
1.1 |
D |
|
Stock Option (right to buy) |
|
04/15/2020 |
Common Stock |
30,000 |
1.1 |
D |
|
Stock Option (right to buy) |
|
04/29/2021 |
Common Stock |
30,000 |
1.8 |
D |
|
Stock Option (right to buy) |
|
04/26/2022 |
Common Stock |
30,000 |
2.25 |
D |
|
Stock Option (right to buy) |
|
05/09/2023 |
Common Stock |
30,000 |
2.5 |
D |
|
Warrant (right to buy) |
|
05/21/2017 |
Common Stock |
813,713 |
0.01 |
D |
|
Warrant (right to buy) |
|
02/07/2018 |
Common Stock |
143,147 |
1.68 |
D |
|
Warrant (right to buy) |
|
08/11/2016 |
Common Stock |
182,000 |
0.01 |
D |
|
Series C Preferred Stock |
|
|
Common Stock |
7,157,346 |
|
I |
See footnote
|
Series D-1 Preferred Stock |
|
|
Common Stock |
5,152,986 |
|
I |
See footnote
|
Series D-2 Preferred Stock |
|
|
Common Stock |
909,090 |
|
I |
See footnote
|
Series D-3 Preferred Stock |
|
|
Common Stock |
825,868 |
|
I |
See footnote
|
Stock Option (right to buy) |
|
03/26/2019 |
Common Stock |
30,000 |
1.1 |
I |
See footnote
|
Stock Option (right to buy) |
|
01/07/2017 |
Common Stock |
30,000 |
1.1 |
I |
See footnote
|
Stock Option (right to buy) |
|
01/07/2018 |
Common Stock |
30,000 |
1.1 |
I |
See footnote
|
Stock Option (right to buy) |
|
04/15/2020 |
Common Stock |
30,000 |
1.1 |
I |
See footnote
|
Stock Option (right to buy) |
|
04/29/2021 |
Common Stock |
30,000 |
1.8 |
I |
See footnote
|
Stock Option (right to buy) |
|
04/26/2022 |
Common Stock |
30,000 |
2.25 |
I |
See footnote
|
Stock Option (right to buy) |
|
05/09/2023 |
Common Stock |
30,000 |
2.5 |
I |
See footnote
|
Warrant (right to buy) |
|
05/21/2017 |
Common Stock |
813,713 |
0.01 |
I |
See footnote
|
Warrant (right to buy) |
|
02/07/2018 |
Common Stock |
143,147 |
1.68 |
I |
See footnote
|
Warrant (right to buy) |
|
08/11/2016 |
Common Stock |
182,000 |
0.01 |
I |
See footnote
|
1. Name and Address of Reporting Person*
(Street)
|
1. Name and Address of Reporting Person*
(Street)
|
Explanation of Responses: |
Remarks: |
|
BERKLEY CAPITAL INVESTORS, L.P., By: BERKLEY CAPITAL, LLC, its general partner, By: /s/ Frank Medici, its President |
07/28/2014 |
|
** Signature of Reporting Person |
Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* If the form is filed by more than one reporting person,
see
Instruction
5
(b)(v). |
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
(5) All securities are held of record by Berkley Capital Investors, L.P., a Delaware limited partnership (“Berkley Investors”). Berkley Capital, LLC, a Delaware limited liability company (“Berkley Capital”) is the general partner of Berkley Investors and as such all securities held by Berkley Investors may be deemed attributable to Berkley Capital. Frank T. Medici and Thomas H. Ghegan are officers of Berkley Capital. The foregoing is not an admission by Berkley Capital that it is the beneficial owner of the securities held of record by Berkley Investors. Each of Messrs. Medici and Ghegan disclaims beneficial ownership of the securities held by Berkley Investors.
JOINT FILERS’ NAMES AND ADDRESSES
The business address for the above reporting persons is:
475 Steamboat Road
Greenwich, CT 06830
JOINT FILERS’ SIGNATURES
BERKLEY CAPITAL, LLC
By: Frank Medici, its President
/s/ Frank Medici
|
7/28/14
|
Signature of Reporting Person
|
Date
|